Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).

Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL.

Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5.

PMID:
30723140
2.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB Jr, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J.

Invest New Drugs. 2018 Dec;36(6):1060-1071. doi: 10.1007/s10637-018-0625-6. Epub 2018 Jul 7.

3.

Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population.

Kawatkar AA, Farias AJ, Chao C, Chen W, Barron R, Vogl FD, Chandler DB.

Support Care Cancer. 2017 Sep;25(9):2787-2795. doi: 10.1007/s00520-017-3692-x. Epub 2017 Apr 10.

4.

A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.

Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA.

Am J Hematol. 2017 Jul;92(7):660-667. doi: 10.1002/ajh.24736. Epub 2017 Jun 5.

5.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA.

Eur J Cancer. 2017 Jan;70:111-121. doi: 10.1016/j.ejca.2016.09.004. Epub 2016 Dec 1.

PMID:
27914241
6.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM.

Gynecol Oncol. 2016 Oct;143(1):27-34. doi: 10.1016/j.ygyno.2016.07.112. Epub 2016 Aug 18.

PMID:
27546885
7.

Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).

Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F.

Ann Oncol. 2016 Jun;27(6):1006-13. doi: 10.1093/annonc/mdw147. Epub 2016 Mar 30.

PMID:
27029706
8.

The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.

Mäenpää J, Varthalitis I, Erdkamp F, Trojan A, Krzemieniecki K, Lindman H, Bendall K, Vogl FD, Verma S.

Breast. 2016 Feb;25:27-33. doi: 10.1016/j.breast.2015.11.007. Epub 2015 Dec 20.

9.

Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.

Xu H, Gong Q, Vogl FD, Reiner M, Page JH.

Support Care Cancer. 2016 Feb;24(2):723-730. doi: 10.1007/s00520-015-2834-2. Epub 2015 Jul 11.

PMID:
26162536
10.

Chemotherapy treatment patterns and neutropenia management in gastric cancer.

Kalinka-Warzocha E, Plazas JG, Mineur L, Salek T, Hendlisz A, DeCosta L, Vogl FD, Passalacqua R.

Gastric Cancer. 2015 Apr;18(2):360-7. doi: 10.1007/s10120-014-0375-x. Epub 2014 May 5.

PMID:
24792482
11.

Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B.

Clin Cancer Res. 2011 May 1;17(9):2967-76. doi: 10.1158/1078-0432.CCR-10-2515. Epub 2011 Mar 17.

12.

Adapted Finnish Migraine-Specific Questionnaire for family studies (FMSQ(FS)): a validation study in two languages.

Facheris MF, Vogl FD, Hollmann S, Sixt G, Pattaro C, Schönhuber R, Pramstaller PP.

Eur J Neurol. 2008 Oct;15(10):1071-4. doi: 10.1111/j.1468-1331.2008.02248.x. Epub 2008 Aug 19.

PMID:
18715259
13.

Disseminated tumor cells: are they ready for clinical use?

Braun S, Vogl FD, Schneitter A, Egle D, Auer D, Lang M, Marth C.

Breast. 2007 Dec;16 Suppl 2:S51-4. Review.

PMID:
17983941
14.

The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives.

Pattaro C, Marroni F, Riegler A, Mascalzoni D, Pichler I, Volpato CB, Dal Cero U, De Grandi A, Egger C, Eisendle A, Fuchsberger C, Gögele M, Pedrotti S, Pinggera GK, Stefanov SA, Vogl FD, Wiedermann CJ, Meitinger T, Pramstaller PP.

BMC Med Genet. 2007 Jun 5;8:29.

15.

Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.

Vogl FD, Badzioch MD, Steele L, Neuhausen SL, Goldgar DE.

Fam Cancer. 2007;6(1):63-71.

PMID:
17051349
16.

Population isolates in South Tyrol and their value for genetic dissection of complex diseases.

Marroni F, Pichler I, De Grandi A, Volpato CB, Vogl FD, Pinggera GK, Bailey-Wilson JE, Pramstaller PP.

Ann Hum Genet. 2006 Nov;70(Pt 6):812-21.

17.

Restless legs syndrome: epidemiological and clinicogenetic study in a South Tyrolean population isolate.

Vogl FD, Pichler I, Adel S, Pinggera GK, Bracco S, De Grandi A, Volpato CB, Aridon P, Mayer T, Meitinger T, Klein C, Casari G, Pramstaller PP.

Mov Disord. 2006 Aug;21(8):1189-95.

PMID:
16685686
18.

A pooled analysis of bone marrow micrometastasis in breast cancer.

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K.

N Engl J Med. 2005 Aug 25;353(8):793-802.

19.

Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis.

Vogl FD, Taioli E, Maugard C, Zheng W, Pinto LF, Ambrosone C, Parl FF, Nedelcheva-Kristensen V, Rebbeck TR, Brennan P, Boffetta P.

Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1473-9.

20.

Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial.

Kuehn T, Vogl FD, Helms G, Pueckler SV, Schirrmeister H, Strueber R, Koretz K, Kreienberg R; German multi-institutional trial.

Eur J Surg Oncol. 2004 Apr;30(3):252-9.

PMID:
15028305
21.

Evaluation of bone marrow in breast cancer patients: prediction of clinical outcome and response to therapy.

Braun S, Vogl FD, Janni W, Marth C, Schlimok G, Pantel K.

Breast. 2003 Dec;12(6):397-404. Review.

22.

p53 autoantibodies can be indicative of the development of breast cancer relapse.

Regele S, Vogl FD, Kohler T, Kreienberg R, Runnebaum IB.

Anticancer Res. 2003 Jan-Feb;23(1B):761-4.

PMID:
12680180
23.

Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study.

Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, Sanders K, Kantemiroff T, Bagha S, Goldgar DE, Narod SA, Foulkes WD.

J Clin Endocrinol Metab. 2001 Nov;86(11):5307-12.

PMID:
11701697
24.

Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.

Vogl FD, Frey M, Kreienberg R, Runnebaum IB.

Br J Cancer. 2000 Nov;83(10):1338-43.

25.

Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients.

Stickeler E, Vogl FD, Denkinger T, Mobus VJ, Kreienberg R, Runnebaum IB.

Int J Mol Med. 2000 Nov;6(5):595-601.

PMID:
11029531
26.

p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells.

Vogl FD, Stickeler E, Weyermann M, Köhler T, Grill HJ, Negri G, Kreienberg R, Runnebaum IB.

Oncology. 1999 Nov;57(4):324-9.

PMID:
10575320
27.

Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.

Regele S, Kohlberger P, Vogl FD, Böhm W, Kreienberg R, Runnebaum IB.

Br J Cancer. 1999 Oct;81(4):702-4.

28.

[Krukenberg tumor: a clinical case report].

Fölsing C, Vogl FD, Karhausen J, Merk J, Kreienberg R, Rieber A.

Rontgenpraxis. 1997 Feb;50(2):31-3. German. No abstract available.

PMID:
9173556

Supplemental Content

Support Center